Maximilian V Malfertheiner1, C Lerzer2, L Kolb3, K Heider3, F Zeman4, F Gfüllner2, L S Maier3, M Pfeifer3,2, M Arzt3. 1. Department of Internal Medicine II, Cardiology and Pneumology, Center for Sleep Medicine, University Medical Center Regensburg, Regensburg, Germany. maximilian.malfertheiner@ukr.de. 2. Center for Pneumology, Donaustauf Hospital, Donaustauf, Germany. 3. Department of Internal Medicine II, Cardiology and Pneumology, Center for Sleep Medicine, University Medical Center Regensburg, Regensburg, Germany. 4. Center for Clinical Studies, University Medical Center Regensburg, Regensburg, Germany.
Abstract
BACKGROUND: Recent evidence has shown that adaptive servo-ventilation (ASV) is contraindicated in patients with predominant central sleep apnea (CSA) and reduced left ventricular ejection fraction (LVEF ≤45%). The objective of this study was to assess the clinical usage of ASV in patients at the time-point of the release of a safety warning by type of SDB, breathing pattern and LVEF. METHODS: Patients of a cardiac and a respirology sleep center, both in Germany, who received ASV therapy were contacted between May and October 2015. Retrospective analyses included diagnostic polysomnography, polysomnography with continuous positive airway pressure prior to ASV initiation and echocardiography. Treatment emergent CSA was diagnosed after an appropriate treatment period on CPAP. RESULTS: 285 patients receiving ASV therapy (91 in the cardiac and 194 in the respirology setting) underwent diagnostic polysomnography. 233 (82%) patients had severe SDB, 94 (33%) predominant CSA, and 185 (65%) periodic breathing. 20% (n = 52) of patients had an LVEF of ≤45%. The most common indications for ASV were CSA in heart failure (41%) in the cardiac setting and treatment emergent CSA (80%) diagnosed after an appropriate period on CPAP in the respirology setting. The proportion of patients in whom ASV was contraindicated (CSA and LVEF ≤45%) was 16% in the cardiac setting and 9% in the respirology setting. CONCLUSION: Clinical usage of ASV changed for a small subgroup of patients after release of the SERVE-HF results. Nevertheless, ASV treatment should be monitored and evaluated with diligence in the reminder indications.
BACKGROUND: Recent evidence has shown that adaptive servo-ventilation (ASV) is contraindicated in patients with predominant central sleep apnea (CSA) and reduced left ventricular ejection fraction (LVEF ≤45%). The objective of this study was to assess the clinical usage of ASV in patients at the time-point of the release of a safety warning by type of SDB, breathing pattern and LVEF. METHODS:Patients of a cardiac and a respirology sleep center, both in Germany, who received ASV therapy were contacted between May and October 2015. Retrospective analyses included diagnostic polysomnography, polysomnography with continuous positive airway pressure prior to ASV initiation and echocardiography. Treatment emergent CSA was diagnosed after an appropriate treatment period on CPAP. RESULTS: 285 patients receiving ASV therapy (91 in the cardiac and 194 in the respirology setting) underwent diagnostic polysomnography. 233 (82%) patients had severe SDB, 94 (33%) predominant CSA, and 185 (65%) periodic breathing. 20% (n = 52) of patients had an LVEF of ≤45%. The most common indications for ASV were CSA in heart failure (41%) in the cardiac setting and treatment emergent CSA (80%) diagnosed after an appropriate period on CPAP in the respirology setting. The proportion of patients in whom ASV was contraindicated (CSA and LVEF ≤45%) was 16% in the cardiac setting and 9% in the respirology setting. CONCLUSION: Clinical usage of ASV changed for a small subgroup of patients after release of the SERVE-HF results. Nevertheless, ASV treatment should be monitored and evaluated with diligence in the reminder indications.
Authors: Dominik Linz; Holger Woehrle; Thomas Bitter; Henrik Fox; Martin R Cowie; Michael Böhm; Olaf Oldenburg Journal: Clin Res Cardiol Date: 2015-04-23 Impact factor: 5.460
Authors: Winfried Randerath; Johan Verbraecken; Stefan Andreas; Michael Arzt; Konrad E Bloch; Thomas Brack; Bertien Buyse; Wilfried De Backer; Danny Joel Eckert; Ludger Grote; Lars Hagmeyer; Jan Hedner; Poul Jennum; Maria Teresa La Rovere; Carla Miltz; Walter T McNicholas; Josep Montserrat; Matthew Naughton; Jean-Louis Pepin; Dirk Pevernagie; Bernd Sanner; Dries Testelmans; Thomy Tonia; Bart Vrijsen; Peter Wijkstra; Patrick Levy Journal: Eur Respir J Date: 2017-01-18 Impact factor: 16.671
Authors: Christine Eulenburg; Karl Wegscheider; Holger Woehrle; Christiane Angermann; Marie-Pia d'Ortho; Erland Erdmann; Patrick Levy; Anita K Simonds; Virend K Somers; Faiez Zannad; Helmut Teschler; Martin R Cowie Journal: Lancet Respir Med Date: 2016-08-31 Impact factor: 30.700
Authors: Thomas Bitter; Nina Westerheide; Mohammed Sajid Hossain; Roman Lehmann; Christian Prinz; Astrid Kleemeyer; Dieter Horstkotte; Olaf Oldenburg Journal: Thorax Date: 2011-03-10 Impact factor: 9.139
Authors: Meghna P Mansukhani; Bhanu Prakas Kolla; James M Naessens; Peter C Gay; Timothy I Morgenthaler Journal: J Clin Sleep Med Date: 2019-01-15 Impact factor: 4.062
Authors: Katharina Heider; Michael Arzt; Christoph Lerzer; Leonie Kolb; Michael Pfeifer; Lars S Maier; Florian Gfüllner; Maximilian Valentin Malfertheiner Journal: Clin Res Cardiol Date: 2018-01-25 Impact factor: 5.460
Authors: Leonie Kolb; Michael Arzt; Stefan Stadler; Katharina Heider; Lars S Maier; Maximilian Malfertheiner Journal: Sleep Breath Date: 2020-09-03 Impact factor: 2.816